Table 2.

Primary and Secondary End Points (Modified Intention-to-Treat Population).^*

End Point	Solanezumab	Placebo
Primary end point: PACC score
No. of participants evaluated†	401	423
Adjusted mean change	−1.43	−1.13
Adjusted mean difference vs. placebo (95% CI)‡	−0.30 (−0.82 to 0.22)
P value	0.26
CFI combined score
No. of participants evaluated†	403	418
Adjusted mean change	2.09	1.51
Adjusted mean difference vs. placebo (95% CI)‡	0.58 (−0.18 to 1.34)
ADL partner score
No. of participants evaluated†	403	419
Adjusted mean change	−2.24	−1.63
Adjusted mean difference vs. placebo (95% CI)‡	−0.61 (−1.44 to 0.23)
CDR-SB score
No. of participants evaluated†	405	421
Adjusted mean change	0.71	0.60
Adjusted mean difference vs. placebo (95% CI)‡	0.12 (−0.06 to 0.29)
Progression of the global CDR score§
No. of participants evaluated†	406	424
Probability of progression at 240 weeks	0.35	0.32

^*Results were analyzed with the use of a spline model, except for progression of the global CDR score, which was assessed in a Kaplan–Meier analysis.

^†Counts include all the participants who had a final visit, which was initially targeted for 240 weeks after randomization. Some participants had evaluations delayed beyond 240 weeks owing to the coronavirus disease 2019 pandemic.

^‡95% confidence intervals were adjusted for multiple testing according to a prespecified graphical testing scheme.

^§Progression of the global CDR score was defined as two consecutive scores greater than zero or a final-visit score greater than zero. Global CDR scores range from 0 to 3, with 0 indicating no cognitive impairment and 3 indicating severe dementia.